@prefix this: . @prefix sub: . @prefix drugbank: . @prefix np: . @prefix mondo: . @prefix pav: . @prefix infores: . @prefix xsd: . @prefix ntemplate: . @prefix orcid: . @prefix rdfs: . @prefix pmid: . @prefix ncit: . @prefix rdf: . @prefix biolink: . @prefix prov: . @prefix npx: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubInfo; a np:Nanopublication . } sub:assertion { drugbank:DB00875 a biolink:Drug; rdfs:label "Flupentixol"; biolink:category biolink:Drug . mondo:0005618 a biolink:Disease; rdfs:label "Anxiety disorder"; biolink:category biolink:Disease . sub:association rdf:object mondo:0005618; rdf:predicate biolink:treats; rdf:subject drugbank:DB00875; a biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation; rdfs:label "First-generation antipsychotics (FGA) use was more than that of second-generation antipsychotics (SGA) use in patients with anxiety disorder through the 9-year period. Sulpiride and flupentixol were the two most common FGA in the treatment of anxiety disorder. Patients with specific anxiety disorder (post-traumatic stress disorder, panic disorder/agoraphobia, generalized anxiety disorder, and obsessive-compulsive disorder), female sex, younger age (age < 65 years), comorbidity with major depression or minor depression, antidepressants concurrent use, and visits to psychiatrists, medical centers and primary care were significantly more likely to take prescribed antipsychotics"; biolink:aggregator_knowledge_source infores:knowledge-collaboratory; biolink:category biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation; biolink:has_population_context sub:context; biolink:publications pmid:31077503; biolink:relation ncit:C94303 . sub:context a biolink:Cohort; rdfs:label "Adults"; biolink:category biolink:Cohort . } sub:provenance { sub:assertion prov:wasAttributedTo orcid:0000-0002-7641-6446 . } sub:pubInfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCR9fz0fKCdWOWC+pxhkQhEM/ppbdIYe5TLSdj+lJzSlv9mYBaPgrzVezSwwbmhlHBPDZa4/vHycU315BdmUGq+pXllp9+rWFfrb+kBJwhZjpG6BeyyXBsRFz4jmQVxl/ZYHilQTh/XalYzKkEAyTiEMPee4Kz61PaWOKH24CsnOQIDAQAB"; npx:hasSignature "B/MqL1xjLnXAbqVYpXDaJZJBTqIX8rJwghk994HWcn+lQV+jjUiCU//POvk8Tu/stai0EnqjVNmxumwuBXqLtJNWc0KytX3YALPlnNIt+I/jgf7kR4kr9EYdeWyoQ+MtLVLBgTi1nRTkUJsHPd1QnowN/6OvyvcbCg7jEdrKqU4="; npx:hasSignatureTarget this: . this: prov:generatedAtTime "2022-09-16T11:51:01.512573"^^xsd:dateTime; prov:wasAttributedTo orcid:0000-0002-1501-1082; ntemplate:wasCreatedFromTemplate . biolink: pav:version "2.3.0" . }